Extended Duration of Adjuvant Temozolomide in Glioblastoma Multiforme - A Review of Trials

被引:0
|
作者
Pruthi, Deep Shankar [1 ]
Nagpal, Puneet [1 ]
Pandey, Manish [1 ]
机构
[1] Act Canc Hosp, Dept Radiat Oncol, A-4, New Delhi, India
来源
EURASIAN JOURNAL OF MEDICINE AND ONCOLOGY | 2021年 / 5卷 / 03期
关键词
Adjuvant; Glioblastoma Multiforme; Extended duration; Temozolomide; NEWLY-DIAGNOSED GLIOBLASTOMA; RANDOMIZED PHASE-III; PROLONGED TEMOZOLOMIDE; OPEN-LABEL; RADIOTHERAPY; CONCOMITANT; SURVIVAL; THERAPY;
D O I
10.14744/ejmo.2021.20733
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Surgical resection followed by concurrent radiation therapy and temozolomide (TMZ) chemotherapy then adjuvant TMZ is the current standard treatment for glioblastoma multiforme (GBM). There is a lot of controversy regarding the duration of adjuvant TMZ. The standard guidelines recommend 6 months of adjuvant treatment, however in clinical practice in a lot of centers around the world, TMZ therapy is continued beyond 6 months duration. In this review article we will discuss both favorable and unfavorable trials regarding extended TMZ therapy and try to analyze in whom extended TMZ therapy is beneficial and whether or not it should be offered.
引用
收藏
页码:217 / 221
页数:5
相关论文
共 50 条
  • [41] 3-D conformal radiotherapy with concomitant and adjuvant temozolomide for patients with glioblastoma multiforme and evaluation of prognostic factors
    Tezcan, Yilmaz
    Koc, Mehmet
    RADIOLOGY AND ONCOLOGY, 2011, 45 (03) : 213 - 219
  • [42] NOVEL APPROACHES TO REDUCE TEMOZOLOMIDE RESISTANCE IN GLIOBLASTOMA MULTIFORME: A REVIEW OF THE LITERATURE
    Jalili, C.
    Rashidi, I.
    Pazhouhi, M.
    WORLD CANCER RESEARCH JOURNAL, 2019, 6
  • [43] Effectiveness of adjuvant temozolomide treatment in patients with glioblastoma
    Alnaami, Ibrahim M.
    Al-Nuaimi, Saleem K.
    Senthilselvan, Ambikaipakan
    Murtha, Albert D.
    Walling, Simon
    Mehta, Vivek
    Gourishankar, Sita
    NEUROSCIENCES, 2013, 18 (04) : 349 - 355
  • [44] The duration of adjuvant temozolomide in patients with glioblastoma and the law of diminishing returns
    Grossman, Stuart A.
    NEURO-ONCOLOGY, 2020, 22 (12) : 1721 - 1722
  • [45] Encouraging experience of concomitant Temozolomide with radiotherapy followed by adjuvant Temozolomide in newly diagnosed glioblastoma multiforme: single institution experience
    Jalali, R.
    Basu, A.
    Gupta, T.
    Munshi, A.
    Menon, H.
    Sarin, R.
    Goel, A.
    BRITISH JOURNAL OF NEUROSURGERY, 2007, 21 (06) : 583 - 587
  • [46] Optimal duration of adjuvant temozolomide in glioblastoma: An unsolved and unsolvable problem
    Balana, Carmen
    NEURO-ONCOLOGY PRACTICE, 2022, 9 (05) : 349 - 350
  • [47] Temozolomide resistance in glioblastoma multiforme
    Lee, Sang Y.
    GENES & DISEASES, 2016, 3 (03) : 198 - 210
  • [48] Long-term adjuvant administration of temozolomide in patients with glioblastoma multiforme: experience of a single institution
    Seiz, Marcel
    Krafft, Ulrich
    Freyschlag, Christian F.
    Weiss, Christel
    Schmieder, Kirsten
    Lohr, Frank
    Wenz, Frederik
    Thome, Claudius
    Tuettenberg, Jochen
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2010, 136 (11) : 1691 - 1695
  • [49] Zinc enhances temozolomide cytotoxicity in glioblastoma multiforme model systems
    Toren, Amos
    Pismenyuk, Tatyana
    Yalon, Michal
    Freedman, Shani
    Simon, Amos J.
    Fisher, Tamar
    Moshe, Itai
    Reichardt, Juergen K. V.
    Constantini, Shlomi
    Mardor, Yael
    Last, David
    Guez, David
    Daniels, Dianne
    Assoulin, Moria
    Mehrian-Shai, Ruty
    ONCOTARGET, 2016, 7 (46) : 74860 - 74871
  • [50] Pseudoprogression in Patients With Glioblastoma Multiforme After Concurrent Radiotherapy and Temozolomide
    Topkan, Erkan
    Topuk, Savas
    Oymak, Ezgi
    Parlak, Cem
    Pehlivan, Berrin
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2012, 35 (03): : 284 - 289